Deracoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C17H14F3N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VX29JB5XWV, chemically known as benzenesulfonamide, 4-(3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1h-pyrazol-1-yl)- but generally known as deracoxib, which bears US NIH Compound Identifier 3058754. European Medicines Agency schedules Deracoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01594MIG. The term DERACOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule deracoxib under HS 29350090 and SITC 51580. As of Q4 2014, DERACOXIB remains the US FDA Preferred Term for this commodity. Deracoxib bears US NLM identifiers UMLS ID C1174840 and NCI Concept Code C73031. SMILES: S(=O)(=O)(N)C1CCC(N2NC(CC2C2CC(F)C(OC)CC2)C(F)F)CC1.